Phase 1 Chronic Kidney Disease Trial, Recruiting NCT06203977 Sponsor: Hamilton Health Sciences Corporation Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 1 Chronic Kidney Disease Trial, Recruiting

NCT06203977
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have significantly reduced kidney function (a specific kidney function score of 30 or below, measured on at least two separate occasions at least 2 months apart), do not currently need dialysis, and are not expected by their kidney doctor to need dialysis within the next 6 months.
  • People who have been receiving regular dialysis (at least twice a week) for the past 90 days.
  • People aged 18 years or older.
  • People who are willing and able to give their informed consent to take part.

Who may not be able to join:

  • People who are currently taking colchicine and cannot stop it for medical reasons.
  • People with a known allergy or sensitivity to colchicine.
  • People who have previously not been able to tolerate colchicine at a dose of 0.6 mg per day or lower.
  • People who are currently pregnant, planning to become pregnant, or planning to breastfeed during the study.
  • People who could become pregnant and either have not had a negative pregnancy test or do not agree to use two forms of contraception for the duration of the study.
  • People who are expected to receive a kidney transplant from a living donor within the next 6 months.
  • People who have taken certain strong medications that affect how the body processes drugs (specifically, strong inhibitors of p-glycoprotein or CYP3A4) in the past 14 days (confirm with trial site if unsure whether a medication applies).
  • People with a Vitamin B12 deficiency that is not being managed with injections.
  • People with ongoing, uncontrolled diarrhoea.
  • People with cirrhosis (scarring of the liver) or chronic active hepatitis (ongoing liver inflammation).
  • People with a pre-existing muscle or nerve disease, or persistently high levels of a muscle enzyme (CK) in their blood in the past 60 days.
  • People who, within the past 60 days, have had blood test results showing: a low white blood cell count, a low platelet count, significantly elevated liver enzymes (ALT or AST), or elevated bilirubin levels (unless due to a harmless inherited condition called Gilbert syndrome).
  • People whom the trial investigator considers unsuitable for the study for any reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Michael Walsh, MD, PhD, McMaster University

Phone: 905-521-2100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Hamilton Health Sciences Corporation
Registry
ClinicalTrials.gov
Start date
15 November 2024
Est. completion
31 May 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Dose tolerance; Early discontinuations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov